Smooth muscle cells (SMC) are primary contributors to the development of arterial disease. The ability of vascular SMC to switch to a proliferative phenotype is one of the main factors in the development and progression of vascular disease. Pulmonary artery smooth muscle cells (PASMC) express VEGF and FGF-2 and are subjected to mechanical forces during pulsatile blood flow. Chronic lung hypoxia causes vascular remodeling with PASMC hyperplasia, and results in pulmonary hypertension. Cultured rat PASMC (RPASMC) play an important role in vascular disease research and can be used to identify new therapeutic targets to treat pulmonary vascular disease.
Recommended Medium: It is recommended to use Smooth Muscle Cell Medium (SMCM, Cat. no. 1101) for culturing RPASMC in vitro.
Product Use: RPASMC are for research use only. They are not approved for human or animal use, or for application in in vitro diagnostic procedures.
Storage: Upon receiving, directly and immediately transfer the cells from dry ice to liquid nitrogen and keep the cells in liquid nitrogen until they are needed for experiments.
Shipping: Dry ice.
References: [1] Schwartz SM, Campbell GR, Campbell JH. (1986) “Replication of smooth muscle cells in vascular disease.” Circ. Res. 58: 427-444.
[2] Quinn TP, Schlueter M, Soifer SJ, Gutierrez JA. (2002) “Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells.” Am. J. Physiol. Lung Cell Mol. Physiol. 282: L897-903.
[3] Rose F, Grimminger F, Appel J, Heller M, Pies V, Weissmann N, Fink L, Schmidt S, Krick S, Camenisch G, Gassmann M, Seeger W, Hänze J. (2002) “Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors.” FASEB J. 12: 1660-1.